Vantage Health Cited in The Atlantic – “A Breathalyzer That Can Diagnose Cancer”
May 14 2014 - 1:46PM
Business Wire
Vantage Health, Inc. (OTCQB: VNTH) ("Vantage Health" or the
"Company"), announced today an article which was published by
Adrienne LaFrance of The Atlantic, an on-line publication and
magazine, entitled “A Breathalyzer That Can Diagnose Cancer”.
For the past two decades, Raed Dweik, a doctor who runs the
pulmonary vascular program at the Cleveland Clinic’s Respiratory
Institute has been studying the molecular patterns in the breath
that can reveal what’s happening inside the body.
Dr. Dweik cites in the article, “The Holy Grail of breath
testing would be a breathalyzer-style device that a person could
carry in her pocketbook and use anytime.”
Vantage Health, Inc. is developing such a device, the Vantage
Health Sensor, with clinical trials planned for later this year. To
view the articles please click on the following links:
http://www.theatlantic.com/health/archive/2014/05/a-breathalyzer-that-can-diagnose-cancer/362102/
https://www.yahoo.com/tech/a-breathalyzer-that-can-diagnose-cancer-85624950229.html
About Vantage Health Inc.
Vantage Health Inc. - a leading mobile health technology company
- is developing personalized and point-of-care screening using Apps
based upon chemical sensing residing within a small device attached
to a smartphone.
With its foundations in advanced nanotechnology, the company’s
first product, the Vantage Health Sensor, is the convergence of
nano-electronics, bio-informatics, and wireless technology to
create the next generation mobile health application. The first
mobile App is expected to be for lung cancer screening with
additional mobile healthcare Apps in the planning stages. The
company has offices in Redwood City, CA and New York. For more
information, please visit http://www.vantagehealthinc.com
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of 1995
that involve risks and uncertainties that could cause actual
results to be materially different from historical results or from
any future results expressed or implied by such forward-looking
statements. Such forward-looking statements include, among other
things statements with respect to our objectives and strategies to
achieve those objectives, as well as statements with respect to our
beliefs, plans, expectations, anticipations, estimates or
intentions. Such forward-looking statements may also include
statements, among other things, concerning the efficacy, safety and
intended utilization of Vantage’s product candidates, the conduct
and results of future clinical trials, plans regarding regulatory
filings, future research and clinical trials and plans regarding
partnering activities. Factors that may cause actual results to
differ materially include, among others, the risk that product
candidates that appeared promising in early research and clinical
trials do not demonstrate safety and/or efficacy in larger-scale or
later clinical trials, trials may have difficulty enrolling,
Vantage may not obtain approval to market its product candidates,
or outside financing may not be available to meet capital
requirements. These forward-looking statements are based on our
current expectations. We caution that all forward-looking
information is inherently uncertain and actual results may differ
materially from the assumptions, estimates or expectations
reflected or contained in the forward-looking information, and that
actual future performance will be affected by a number of factors,
including economic conditions, technological change, regulatory
change and competitive factors, many of which are beyond our
control. Therefore, future events and results may vary
significantly from what we currently foresee.
For a further list and description of the risks and
uncertainties the Company faces, please refer to the Company’s most
recent Annual Report on Form 10-K and other periodic and other
filings Vantage files with the Securities and Exchange Commission
and are available at www.sec.gov. Such forward-looking statements
are current only as of the date they are made, and Vantage assumes
no obligation to update any forward-looking statements, whether as
a result of new information, future events or otherwise.
Investors:CSIR Group, LLC.Christine Petraglia212-386-7082
Nano Mobile Healthcare (PK) (USOTC:VNTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nano Mobile Healthcare (PK) (USOTC:VNTH)
Historical Stock Chart
From Jul 2023 to Jul 2024